Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
Saved in:
| Title: | Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. |
|---|---|
| Authors: | de Almeida, Daniel Vargas P.1,2, Anderson, Justine M.1,3, Danila, Daniel C.1,4, Morris, Michael J.1,4, Slovin, Susan F.1,4, Abida, Wassim1,4, Cohn, Erica D.1,5, Baser, Raymond E.6, Scher, Howard I.1,4,7, Autio, Karen A.1,4 AutioK@mskcc.org |
| Source: | Journal of Immunotherapy & Precision Oncology. Nov2023, Vol. 6 Issue 4, p162-169. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
